For years, cancer immunotherapy has focused heavily on T cells — but a new study from the Salk Institute suggests we've been overlooking a powerful ally: B cells. Published in Cell Reports on September 10, 2026, the research is the first to demonstrate that B cells can mechanistically regulate CD8+ "killer" T cell function, not just correlate with better patient outcomes.

Using a mouse model of triple-negative breast cancer (a notoriously hard-to-treat cancer), the team found that activating the CD40 signaling pathway on B cells triggered a cascade of anti-tumor activity. B cells helped recruit CD8+ T cells into tumors, organized their positioning once inside, and directly signaled them to switch on their cancer-killing functions.

Key Takeaways:

• B cells were shown to drive CD8+ T cell recruitment, organization, and cytotoxic activation within tumors — a first-of-its-kind mechanistic finding
• The effect was most pronounced in high-mutation-burden breast cancer models, where more neoantigens (abnormal cancer proteins) are present
• CD40 is already an active clinical drug target in triple-negative breast cancer trials, making these findings immediately relevant

Why it matters: This research shifts B cells from bystanders to central players in anti-tumor immunity, laying the groundwork for B cell-targeted immunotherapies that could help patients who don't respond to current T cell-based treatments.